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PURPOSE. We previously identified the presence of the melanocyte-specific secreted (ME20-S)
glycoprotein in secretomes of uveal melanoma (UM) cultures. The aim of this study was to
test for the presence and levels of ME20-S in the serum of patients with choroidal nevi and UM
and correlate these levels with individual clinical data.
METHODS. Serum ME20-S levels were determined by ELISA in 111 patients distributed into four
categories (53 choroidal nevi, 30 untreated UM, 11 10-year disease-free [DF] UM, 17 hepatic
metastatic UM) and 32 age- and sex-matched controls. ME20-S levels were correlated with
individual clinical data.
RESULTS. The UM and the metastatic groups showed significantly higher levels of serum ME20-
S than the other groups (P < 0.001). ME20-S levels in the DF patients did not differ from those
in the control group. In addition, log-transformed serum ME20-S levels showed a positive
correlation with the thickness of the lesion mass in UM patients (regression coefficient
0.0689, 95% confidence interval 0.0689–0.1123, R2 ¼ 27.1%).
CONCLUSIONS. Elevated ME20-S serum levels are associated with tumor size and advanced stages
of UM while low levels are characteristic of DF patients. ME20-S might be a promising serum
marker for UM and useful for monitoring metastatic disease.
Keywords: melanocyte protein PMEL, M20-S, uveal melanoma, choroidal nevi, circulating
biomarker
As the most common primary malignant intraocular tumor,uveal melanoma (UM) is also the main intraocular disease
that can be fatal in adults. Its incidence in the general
population is 5.3 to 10.9 cases per million people per year.1,2
Uveal melanoma disseminates mainly through the bloodstream
and preferentially metastasizes to the liver.3 Even with
successful treatment of primary UM tumors, patients remain
at risk of developing metastases for more than 20 years after
initial diagnosis.4 In the Collaborative Ocular Melanoma Study,
Kaplan-Meier analysis estimated 2-, 5-, and 10-year metastasis
rates of 10%, 25%, and 34%, respectively. However, only 0.24%
of the patients exhibited detectable metastases at the time of
diagnosis.5 In this regard, the metastatic rate has been related to
the tumor height.6
Poor prognosis is associated with various clinical and
molecular factors of the primary UM, such as tumor height,6
presence of monosomy 3, and gain of chromosome 8.7,8 More
recently, UM research has evolved toward finding genetic
prognostic markers to identify patients at risk for developing
metastatic disease. In particular, tumor-specific mutations have
been found in the GNAQ, GNA11, and BAP1 genes.9–11 In
addition, gene expression profiling from fine-needle biopsies
has emerged as a powerful tool for molecular prognostication
in UM, able to discern low- and high-risk patients.12,13 However,
the risk of underestimating the prognostic probability of
metastasis and metastasis death by fine-needle aspiration biopsy
has to be considered.14 Under this scenario, the identification
of noninvasive blood biomarkers could have a crucial impact in
the management of UM. Ideally, these prognostic markers
would be effective for assessment of metastatic risk and guiding
follow-up as well as facilitating adjuvant therapy decisions.
We previously applied proteomics technology to detect UM
tumor-specific proteins released into the extracellular sur-
roundings and presumably to the blood circulation.15 We
identified several potential UM biomarkers, including the 95-
kDa premelanosome protein (PMEL), also known as glycopro-
tein 100 (gp100) and melanoma-associated ME20 (ME20M), and
the oncoprotein PARK7/DJ-1. Both proteins, DJ-1 and the
ME20M soluble form (ME20-S), were detected in the serum of
patients with UM.15–17 Thereafter, a larger survey enabled us to
describe for the first time that elevated serum levels of DJ-1 are
associated with choroidal nevi transformation risk factors.18
ME20M is thought to be an oncofetal self-antigen that is
normally expressed at low levels in quiescent adult melano-
cytes, but is overexpressed by proliferating neonatal melano-
cytes and during tumor growth.19 Because it is considered a
tumor-associated antigen that is specific to patients with
cutaneous melanoma,20 monoclonal antibodies against this
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protein are routinely used in melanoma diagnosis.21 ME20M
has a central role in melanosome biogenesis, mediating the
maturation of melanosomes from stage I to stage II.20
Moreover, the secretion of the soluble form, ME20-S, has been
suggested to protect melanoma cells from antibody-mediated
immunity.22 Taking into account the melanoma-specific nature
of this molecule, we hypothesize that it could be a good UM
biomarker candidate.
The purpose of the present study was to test for the presence
and assay the levels of circulating ME20-S in patients with
choroidal nevi and UM and correlate this with individual clinical
data to evaluate its potential as an individual prognostic factor.
METHODS
Patients
This study was based on serum samples from 111 patients at
the Ocular Oncology Unit at the Complexo Hospitalario
Universitario de Santiago (Spain) and at the Catalan Institute
of Oncology (Barcelona, Spain) collected between January
2009 and May 2015. The study groups were classified as
choroidal nevi group (n¼ 53), UM group comprising patients
with untreated UM (n ¼ 30), disease-free UM (DFUM) group
comprising disease-free UM patients who were previously
treated by brachytherapy and/or enucleation and who did not
develop metastasis for at least 10 years from diagnosis (n¼11),
and patients who developed hepatic metastasis after local
treatment (n ¼ 17). Patients comprising the untreated UM
group were classified as stage I or II, stage III (A, B), and stage
IIIC according to American Joint Committee on Cancer (AJCC)
staging23; serum samples in this group of patients were always
extracted prior to treatment. Clinical diagnosis was made on
the basis of complete ophthalmic examination and standard-
ized ocular ultrasonography.
Inclusion criteria for the nevi group were the presence of
one nevus up to 2.9 mm in thickness and a large basal diameter
(LBD) less than 12 mm based on ocular ultrasonography or
fundus retinography. Clinical signs of prognostic value for nevi
transformation were evaluated in all cases. These included the
following: presence of ophthalmic symptoms directly related
to the tumor (floaters, photopsias, and visual acuity diminu-
tion), drusen affecting the overlying retina, presence of orange
pigment, and tumor margin within 3 mm of the optic disc.24,25
Treatment was not indicated for any choroidal nevus, as none
exhibited sufficient evidence of risk. Thickness measurement
was determined by ultrasonographic study, except in nine
cases in which the thickness was not sufficiently large to be
detected by the ultrasonic signal. In these nine cases, thickness
was assumed not to exceed 0.5 mm.26
In the DFUM group of patients, eight patients were treated
with brachytherapy using I-125 and three patients by primary
enucleation. These patients were treated at a minimum of 10
years before blood collection. In order to detect metastasis, the
evaluation included abdominal ultrasonography and blood
samples for liver function tests and serum biomarkers (alkaline-
phosphatase [AP], aspartate aminotransferase [AST/GOT],
alanine aminotransferase [ALT/GPT], lactate dehydrogenase
[LDH], and gamma-glutamyl transpeptidase [GGT]). Upon
detection of a suspicious mass on abdominal ultrasonography,
patients underwent magnetic resonance imaging (MRI) for
confirmation. Exclusion criteria were prior history of any type
of cancer and the presence of suspicious cutaneous melano-
cytic lesions.
As a control group, 32 healthy volunteers were selected
from among individuals undergoing routine ophthalmologic
examinations. This group was matched in age and sex
distribution and had the same exclusion criteria as the patient
groups. Individuals from all groups were exposed to identical
clinical procedures. All participants provided written informed
consent, according to the Declaration of Helsinki, prior to
participation in the study, which was approved by the Comité
Ético de Investigación Cĺınica de Galicia (Spain).
Clinical Procedures
Standardized ultrasonography was performed using the I3-ABD
System (Innovative Imaging, Inc., Sacramento, CA, USA) with a
10-MHz probe. After the instillation of anesthetic drops,
topographic, quantitative, and kinetic ultrasound27 was per-
formed directly over the eye using a coupling gel (Viscotears,
carbomer gel 2%; Novartis, Barcelona, Spain). The same physician
performed this examination in all patients. The following acoustic
parameters were studied: tumor location, LBD and thickness, and
the presence of acoustic hollowness. The existence of subretinal
fluid related to the tumor was examined by Cirrus SD-OCT (Carl
Zeiss Meditec, Inc., Jena, Germany).
Blood samples for ME20-S serum detection were collected
in STT II Advance Vacutainer tubes (Ref. 368967; Becton-
Dickinson, Franklin Lakes, NJ, USA). Samples were allowed to
clot for 30 minutes. They were then centrifuged for 15 minutes
at 1500g to separate the serum. Serum samples were
immediately aliquoted, coded, and frozen at 808C until
processing. Clinical information and data collected from the
patient sera were double masked.
Enzyme-Linked Immunosorbent Assay (ELISA)
Serum levels of ME20-S were quantified with the Melanoma-
Associated ME20 kit (USCN Life Science, Inc., Wuhan, PR
China) according to the manufacturer’s instructions. Absor-
bance from each sample was measured in duplicate with a
spectrophotometric microplate reader at 450 nm (VersaMax
Microplate Reader; Molecular Devices, CA, USA).
Statistical Analysis
Differences in ME20-S values between patient groups were
analyzed by nonparametric Kruskal-Wallis and Mann-Whitney
tests due to the nonnormal data distribution. Holm’s method
was used to adjust for multiple comparisons.28 Relationships of
LBD and thickness measurements with ME20-S levels (as the
dependent variable) were analyzed by additive regression
models (AMs), which were used to avoid imposing arbitrary
parametric effects.29 Both relationships were linear; therefore,
a linear regression model was fitted, and the ME20-S levels
were log transformed to achieve normality. Regression results
are expressed in terms of the regression coefficient (RC), 95%
confidence interval (95% CI), and proportion of the variability
explained (R2). All statistical analyses were performed in the R
software package (version 2.15.1).30 Additive regression
models were fitted with the mgcv package.31 A P value <
0.05 was considered statistically significant in all tests.
RESULTS
Clinical Findings
The subjects comprised 111 Caucasian patients with a mean
age of 63 years (range, 42–81). Among these patients, 41 were
diagnosed with UM with a mean age of 67 years (range, 35–87),
53 with choroidal nevi with a mean age of 65 years (range, 23–
91) and 17 with hepatic metastases of UM with a mean age of
66 years (range, 41–83). The control group comprised 32
individuals with a mean age of 66 years (range, 26–98). There
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were no statistically significant differences in the age or sex
distribution between groups.
Within the measurable nevi group (n ¼ 38, height > 0.50
mm), the median thickness was 1.30 mm (interquartile range
[IQR] ¼ [0.83; 1.82]) and median LBD was 5.61 mm (IQR ¼
[4.79; 8.32]). Median tumor thickness of the untreated UM
group was 7.51 mm (IQR¼ [4.81; 10.82]) and median LBD was
11.46 mm (IQR ¼ [10.35; 13.17]). In the DFUM group, those
patients previously treated by brachytherapy showed a median
thickness of 4.67 mm (IQR¼ [3.83; 6.82]) and a median LBD of
10.9 mm (IQR ¼ [8.50; 11.6]).
With respect to patients treated with enucleation, they
showed a median height of 11.13 mm (IQR¼ [8.32; 14.23] and
a median LBD of 12.9 mm (IQR¼ [8.50; 13.6]). Median primary
tumor thickness of the metastatic group was 10.00 mm (IQR¼
[6.87; 13.02]), and median LBD was 11.46 mm (IQR¼ [11.00;
16.94]).
ME20-S Serum Levels
Serum levels of ME20-S differed significantly between groups
(Kruskal-Wallis, P < 0.001; Fig. 1). Specifically, serum ME20-S
levels diverged significantly between the choroidal nevi group
(0.73 ng/mL, IQR ¼ [0.43; 1.36]) and the UM group (6.92 ng/
mL, IQR ¼ [3.44; 11.7]; Mann-Whitney test, P < 0.001).
Moreover, serum ME20-S levels in the DFUM patient group
(0.37 ng/mL, IQR¼ [0.31; 0.49]) were lower than those in the
UM group (Mann-Whitney test, P < 0.001) and than those in
the choroidal nevi group (Mann-Whitney test, P ¼ 0.027).
Although serum ME20-S levels in the DFUM patients did not
differ from those in the control group (0.70 ng/mL, IQR ¼
[0.38; 1.05]) (Mann-Whitney test, P¼ 0.052), ME20-S levels in
the control group were significantly different from those in the
UM group (Mann-Whitney test, P < 0.001) and the choroidal
nevi group (Mann-Whitney test, P < 0.001) (Fig. 1). The most
striking result was that there was significant difference
between DFUM patients and those presenting with metastasis
(4.21 ng/mL, IQR ¼ [2.83; 4.96]; Mann-Whitney test, P <
0.001). Both the UM and the metastatic group showed
significantly greater levels of circulating ME20-S compared to
the rest of the groups (Table).
In the choroidal nevi group, no statistically significant
differences were detected in ME20-S serum levels between
groups defined by the presence of known risk factors of
malignant transformation (orange pigment, choroidal excava-
tion, fluid, or the absence of drusen) (Supplementary Table
S1).
When specifically studying the group of untreated UM
patients, we found that there were differences in the
concentration of ME20-S among the different stages of the
disease as classified by the AJCC staging. Stages I and II showed
a concentration of 3.01 ng [1.88; 3.66], while those in stages III
(A, B) and IIIC revealed higher levels, 7.74 ng [5.03; 9.62] and
16.00 ng [12.60; 35.38], respectively (P ¼ 0.005). In addition,
we found that serum ME20-S levels were associated with
untreated UM tumor size. Log-transformed serum ME20-S levels
were positively associated with UM thickness (RC 0.0689, 95%
CI 0.0251–0.1123, R2 ¼ 27.1%, P ¼ 0.003), although the
relationship was weak (Fig. 2). A deeper study considering the
clinical characteristics of untreated UM patients detected
higher concentrations of ME20-S in patients with extrascleral
extension and in those with pigmented melanomas compared
to amelanotic (P < 0.05). No differences were observed based
on the cell type (fusiform, mixed, and epithelial), location, or
the presence of associated retinal detachment.
FIGURE 1. Logarithmic scale representation of serum ME20-S levels in
five groups of patients (control, choroidal nevi, untreated UM, 10-year
disease-free [DFUM], hepatic metastatic UM). Vertical lines indicate the
range, and horizontal boundaries of the boxes represent the first and
third quartiles. Significance level: ***P < 0.001.
TABLE. Comparisons of ME20-S for Each Patient Group
Group P Value




Choroidal nevi UM <0.001
DFUM 0.0271
Metastasis <0.001
Uveal melanoma DFUM <0.001
Metastasis 0.0240
DFUM Metastasis <0.001
P values are based on nonparametric Mann-Whitney test (corrected
by Holm method).
FIGURE 2. Relationship between log-transformed ME20-S values and
tumor thickness. Linear regression estimation (solid line) of the
relationship between ME20-S levels and UM thickness together with
point-wise 95% confidence intervals (dotted line).
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DISCUSSION
Our study demonstrates for the first time a positive correlation
between serum ME20-S protein levels and UM tumor thickness.
While those patients with treated UM (DFUM) showed no
significant differences compared to healthy individuals, in the
present work we show that increased serum ME20-S levels are
positively associated with the presence of nontreated UM and
the existence of UM metastatic disease.
Despite significant advances in UM diagnosis and treatment,
the prognosis for this type of tumor remains poor. Metastatic
liver disease is the leading cause of death in patients with UM
and can develop after a long disease-free interval, suggesting
the presence of hidden micrometastases seeded prior to local
treatment.32 Thus, the ability to monitor tumor progression by
assaying malignancy indicators would be very valuable. The
discovery of tumor-specific biomarkers has been a challenge
for cancer research for decades. Unfortunately, very few
markers have been found to be useful in a routine clinical
setting, stressing the need for new clinically relevant sources
such as proteomics.33 Uveal melanoma tumor cells secrete
proteins into the tumor environment that subsequently spread
through the surrounding vascular networks and into the blood
circulation.16 Therefore, proteins secreted by tumor cells,
which could be detected by a simple blood test, could be
potential biomarkers for disease diagnosis and/or prognosis.
Serum biomarkers have an advantage over histopathologic
biomarkers in that it is not necessary to obtain tissue samples
from the primary tumor or metastasis. Therefore, serum
markers may be used to monitor patients with UM. The
identification and characterization of ME20M protein and its
soluble form ME20-S in UM have the advantage that it is a
structural protein and specific for melanoma as compared to
other nonspecific markers investigated previously.34–36 In
support of this hypothesis, it is important to note that
ME20M has been recently used as a therapeutic target for
drug conjugate therapy in cutaneous melanoma.37
We previously demonstrated that UM cells secrete ME20-S
into the extracellular environment and into the bloodstream.16
Protein ME20M (gp100) is specific to normal and malignant
melanocyte lineage cells, and its presence is routinely assessed
in the diagnosis of malignant cutaneous and UM, as it is a tumor
antigen expressed by more than 75% of human melano-
mas.34,38 Little attention, however, has been paid to the soluble
from (ME20-S) of this protein as a circulating biomarker.
Because the melanocyte protein ME20M is a structural protein
found in the membrane of melanocytes, it is reasonable to
hypothesize that serum ME20-S values could correlate with the
number of cells comprising the tumor mass and the existence
of UM metastases.20 Although the precise mechanism respon-
sible for ME20-S shedding is as yet unclear, it was recently
postulated that ME20-S is released by ectodomain shedding
through regulated proteolysis not only at the cell surface but
also via intracellular compartments such as exosomes.34
In light of the small sample size used in the current study,
caution must be taken in interpreting the results. Further
analyses using larger sample sizes and during follow-up are
essential for determining the use of the ME20-S level as a
biomarker. Unfortunately, our Retinal Oncology Unit was
unable to perform gene expression or chromosome analysis
in the early stages of the study. In the future, it would be
valuable to increase the number of patients in the sample and
to include the above-mentioned variables.
To our knowledge, this is the first report detecting the
soluble form of melanocyte protein ME20-S in the circulation of
UM patients. The most significant finding from this study is that
elevated ME20-S serum levels were associated with tumor
thickness and advanced stages of the disease while low levels
are characteristic of patients free of disease. Taken together,
these results suggest that serum ME20-S determination might
be useful as a potential serologic biomarker for UM.
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